Evaluation of Ischemic Modified Albumin Levels in Coronavirus Disease 2019-Positive and -Negative Patients with Acute Cardiac Injury
1Department of Clinical Microbiology, İstanbul University of Health Sciences, Mehmet Akif Ersoy Thoracic Cardiovascular Surgery Training and Research Hospital, İstanbul, Türkiye
2Department of Rare Diseases, İstanbul University, Institute of Health Sciences, İstanbul, Türkiye
3Department of Cardiology, İstanbul University of Health Sciences, Mehmet Akif Ersoy Thoracic Cardiovascular Surgery Training and Research Hospital, İstanbul, Türkiye
Anatol J Cardiol 2023; 12(27): 706-711 PubMed ID: 37804148 DOI: 10.14744/AnatolJCardiol.2023.3431
Full Text PDF

Abstract

Background: The severe acute respiratory syndrome coronavirus 2 is the source of the global pandemic known as coronavirus disease 2019, and the disease prognosis is also linked to the prevalence of cardiac problems. In our study, we aimed to contribute to the early diagnosis and treatment of cardiac complications by evaluating ischemic modified albumin levels in adults with coronavirus disease 2019 disease.

Materials and Methods: Our study was conducted with a total of 176 cases: group 1 (n = 70) with cardiac injury and coronavirus disease 2019 (+), group 2 (n = 57) with cardiac injury and coronavirus disease (−), and group 3 (n = 49) with healthy volunteers. The Mann–Whitney U test, the average, SD, minimum and maximum values, intergroup comparison of the results, and
statistical significance were evaluated with the Pearson correlation coefficient.

Results: As a result of the bilateral comparisons, ischemic modified albumin measurements of the coronavirus disease 2019 (+) and coronavirus disease 2019 (−) groups were higher than the control group (P =.006 and P =.006, respectively). There was no statisti-cally significant difference between ischemic modified albumin measurements of coronavirus disease 2019 (+) and coronavirus disease 2019 (−) groups.

Conclusion: Ischemic modified albumin measurement accelerates the diagnosis and treatment process in the evaluation of cardiac injuries in coronavirus disease 2019 patients.